Pharmacokinetics of Caspofungin (Cancidas ®) Given Intravenously as Therapy to Patients With an Invasive Fungal Infection in the Intensive Care Unit - a Search for Co-variates

• Status: Completed
• Trial end date: 2013-06-01
• Target enrollment: 0
• Participant gender: All

Summary

The pharmacokinetics of caspofungin are expected to be different in ICU patients compared to non-ICU patients. The investigators will determine caspofungin concentrations in 20 ICU patients, who will get caspofungin as standard care.

Full PK curves will be taken on day 3 and a limited PK curve on day 7, trough levels will be taken daily.

• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Radboud University
• Treatments: Caspofungin; Echinocandins

Criteria

Inclusion Criteria:

• Patient is admitted to an ICU

• Subject is at least 18 and not older than 65 years of age on the day of the first dosing

• Subject has been treated with caspofungin for a maximum of two days before enrolment in this trial

• Is managed with a central venous catheter

Exclusion Criteria:

• Is known to be hypersensitive to echinocandin antifungal agents

• Documented history of sensitivity to medicinal products or excipients similar to those found in the caspofungin preparation

• Positive HIV test or hepatitis B or C test

• History of QT time prolongation

• History of or current abuse of drugs, alcohol or solvents

• Has previously participated in this trial